SEI Investments’s Ocular Therapeutix OCUL Stock Holding History

SEI Investments’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.05M	Sell	208,650 -49,514	-19%	-$449K	﹤0.01%	1944
2026 Q1	$2.19M	Buy	258,164 +88,491	+52%	+$843K	﹤0.01%	1962
2025 Q4	$2.06M	Buy	169,673 +53,559	+46%	+$651K	﹤0.01%	1839
2025 Q3	$1.36M	Sell	116,114 -37,556	-24%	-$449K	﹤0.01%	1848
2025 Q2	$1.43M	Buy	153,670 +9,321	+6%	+$73K	﹤0.01%	1778
2025 Q1	$1.06M	Buy	144,349 +116,607	+420%	+$896K	﹤0.01%	1883
2024 Q4	$237K	Buy	27,742 +4,496	+19%	+$43.9K	﹤0.01%	2431
2024 Q3	$202K	Buy	+23,246	New	+$192K	﹤0.01%	2475
2021 Q2	–	Sell	-75,250	Closed	-$1.48M	–	2607
2021 Q1	$1.48M	Buy	75,250 +19,130	+34%	+$368K	﹤0.01%	1593
2020 Q4	$1.16M	Buy	56,120 +45,790	+443%	+$680K	﹤0.01%	1634
2020 Q3	$79K	Buy	+10,330	New	+$85.7K	﹤0.01%	2351
2018 Q2	–	Sell	-5,000	Closed	-$33K	–	3734
2018 Q1	$33K	Buy	+5,000	New	+$28.1K	﹤0.01%	2489
2015 Q4	–	Sell	-600	Closed	-$8K	–	2636
2015 Q3	$8K	Buy	+600	New	+$12.1K	﹤0.01%	2215

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SEI Investments's OCUL Position: Q2 2026 in Review

SEI Investments reduced its Ocular Therapeutix (OCUL) stake by 19% in Q2 2026, selling an estimated $449K and leaving 208,650 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1944.

SEI Investments first reported a position in OCUL in Q3 2015 and has held it in 13 quarters since. The position peaked at $2.19M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

SEI Investments held 208,650 shares of Ocular Therapeutix worth $2.05M as of Q2 2026.
SEI Investments sold 49,514 Ocular Therapeutix shares in Q2 2026, an estimated $449K.
Ocular Therapeutix made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #1944 holding.
SEI Investments first reported a position in Ocular Therapeutix in Q3 2015 and has held it in 13 quarters since.
SEI Investments's Ocular Therapeutix position peaked at $2.19M in Q1 2026.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.